Results for tag: "Sclerostin Inhibitor"

The Sclerostin Inhibitor market is a subset of the Musculoskeletal Disorders Drugs market. It is composed of drugs that target sclerostin, a protein that inhibits bone formation. These drugs are used to treat osteoporosis, a condition characterized by weak and brittle bones. Sclerostin inhibitors are designed to increase bone formation and reduce the risk of fractures. They are also used to treat other bone-related conditions, such as osteopenia and Paget's disease. The Sclerostin Inhibitor market is expected to grow in the coming years due to the increasing prevalence of musculoskeletal disorders. The rising demand for effective treatments is also driving the market. Some of the major companies in the Sclerostin Inhibitor market include Amgen, Eli Lilly, Merck, Novartis, and Pfizer. These companies are actively developing and marketing sclerostin inhibitors for the treatment of musculoskeletal disorders. Show Less Read more